摘要
超极化活性核苷酸循环渠道在心脏窦房结细胞和不成熟的心肌细胞起搏活动的传递中发挥重要作用。HCN通道也存在于成人心房和心室心肌细胞,当前其生理作用正在研究中。已经提出,在不同的心脏疾病,HCN通道功能失调是心率失常的直接原因。虽然HCN通道功能损失突变与窦性心动过缓有关,HCN通道在房颤、心室肥大和心衰的正常功能可能促进了异位电活动、促进心律失常。 利用ivabradine 来阻塞HCN通道,是目前临床使用的一种选择性减慢心率的药物,可改善心脏性能和抵消功能性重构。因此,ivabradine可以改善慢性心力衰竭患者的症状。目前,正在研究开发新颖的、选择性强的心脏HCN亚型通道的药物。
关键词: 心率失常,房室结,心肌肥大,心肌细胞,HCN通道,窦房结
Current Drug Targets
Title:Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Volume: 16 Issue: 8
Author(s): Laura Sartiani, Maria Novella Romanelli, Alessandro Mugelli and Elisabetta Cerbai
Affiliation:
关键词: 心率失常,房室结,心肌肥大,心肌细胞,HCN通道,窦房结
摘要: The hyperpolarization-activated cyclic nucleotide-gated (HCN) channels play an important role in the generation of pacemaker activity of cardiac sinoatrial node cells and immature cardiomyocytes. HCN channels are also present in adult atrial and ventricular cardiomyocytes, where the physiological role is currently under investigation. In different cardiac pathologies, dysfunctional HCN channels have been suggested to be a direct cause of rhythm disorders. While loss-of-function mutations of HCN channels are associated with sinus bradycardia, HCN channel gain-of-function in atrial fibrillation, ventricular hypertrophy and failure might help enhance ectopic electrical activity and promote arrhythmogenesis. Blockade of HCN channels with ivabradine, a selective bradycardic agent currently available for clinical use, improves cardiac performance and counteracts functional remodeling in experimental hypertrophy. Accordingly, ivabradine ameliorates clinical outcome in patients with chronic heart failure. Novel compounds with enhanced selectivity for cardiac HCN channel isoforms are being studied as potential candidates for new drug development.
Export Options
About this article
Cite this article as:
Laura Sartiani, Maria Novella Romanelli, Alessandro Mugelli and Elisabetta Cerbai , Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150531152047
DOI https://dx.doi.org/10.2174/1389450116666150531152047 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Current Vascular Pharmacology Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention
Current Medicinal Chemistry Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis
Current Pharmaceutical Design Agonist-Trafficking and Hallucinogens
Current Medicinal Chemistry Patient Engagement in Randomized Controlled Tai Chi Clinical Trials among the Chronically Ill
Reviews on Recent Clinical Trials The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives - A Review
Current Pharmaceutical Analysis Cigarette Smoke-Induced Proteostasis Imbalance in Obstructive Lung Diseases
Current Molecular Medicine Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery The Zebrafish as a Novel Tool for Cardiovascular Drug Discovery
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
Reviews on Recent Clinical Trials Editorial [Hot topic: Brave New World? Arrestin Pathway Bias in Drug Design (Guest Editor: Bradley T. Andresen)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Effects on Cytokines and Histology by Treatment with the Ace Inhibitor Captopril and the Antioxidant Retinoic Acid in the Monocrotaline Model of Experimentally Induced Lung Fibrosis
Current Pharmaceutical Design